Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

599 ARTÍCULOS , VIENDO DEL 226 AL 240

A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice

Pagonabarraga J, Arbelo JM, Grandas F, Luquin MR, Martínez Martín P, Rodríguez-Oroz MC, Valldeoriola F, Kulisevsky J.

Brain Sci. 2020 Mar 18;10(3):176. doi: 10.3390/brainsci10030176.

A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia

Svenningsson P, Odin P, Dizdar N, Johansson A, Grigoriou S, Tsitsi P, Wictorin K, Bergquist F, Nyholm D, Rinne J, Hansson F, Sonesson C, Tedroff J; IRL752 Collaborators.

Mov Disord. 2020 Jun;35(6):1046-1054. doi: 10.1002/mds.28020. Epub 2020 Mar 21.

[Psychosis and movement disorders in an adolescent with 22q11.2 deletion syndrome]

Zinkstok JR, Velders F, Rieken R, Houben M, Fiksinski A, van Amelsvoort TAMJ, Boot E.

Tijdschr Psychiatr. 2020;62(3):229-233.

Factor Analysis and Clustering of the Movement Disorder Society-Non-Motor Rating Scale

Martinez-Martin P, Rojo-Abuín JM, Weintraub D, Chaudhuri KR, Rodriguez-Blázquez C, Rizos A, Schrag A.

Mov Disord. 2020 Jun;35(6):969-975. doi: 10.1002/mds.28002. Epub 2020 Mar 27.

A Novel DBS Paradigm for Axial Features in Parkinson's Disease: A Randomized Crossover Study

Karl JA, Ouyang B, Goetz S, Metman LV.

Mov Disord. 2020 Aug;35(8):1369-1378. doi: 10.1002/mds.28048. Epub 2020 Apr 4.

Animal models for preclinical Parkinson's research: An update and critical appraisal

Cenci MA, Björklund A.

Prog Brain Res. 2020;252:27-59. doi: 10.1016/bs.pbr.2020.02.003. Epub 2020 Mar 21.

Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients

Olanow CW, Standaert DG, Kieburtz K, Viegas TX, Moreadith R.

Mov Disord. 2020 Jun;35(6):1055-1061. doi: 10.1002/mds.28027. Epub 2020 Apr 6.

Historical Perspective: Models of Parkinson's Disease

Chia SJ, Tan EK, Chao YX.

Int J Mol Sci. 2020 Apr 2;21(7):2464. doi: 10.3390/ijms21072464.

Diphasic Worsening of Freezing of Gait in Parkinson's Disease

Perez Parra S, McKay JL, Factor SA.

Mov Disord Clin Pract. 2020 Mar 9;7(3):325-328. doi: 10.1002/mdc3.12918. eCollection 2020 Apr.

Additional Physical Interventions to Conventional Physical Therapy in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Hidalgo-Agudo RD, Lucena-Anton D, Luque-Moreno C, Heredia-Rizo AM, Moral-Munoz JA.

J Clin Med. 2020 Apr 7;9(4):1038. doi: 10.3390/jcm9041038.

Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease

Poewe W, Mahlknecht P.

Neurol Clin. 2020 May;38(2):255-267. doi: 10.1016/j.ncl.2019.12.002. Epub 2020 Feb 20.

Update on the Management of Parkinson's Disease for General Neurologists

Pirtošek Z, Bajenaru O, Kovács N, Milanov I, Relja M, Skorvanek M.

Parkinsons Dis. 2020 Mar 26;2020:9131474. doi: 10.1155/2020/9131474. eCollection 2020.

Photobiomodulation for Parkinson's Disease in Animal Models: A Systematic Review

Salehpour F, Hamblin MR.

Biomolecules. 2020 Apr 15;10(4):610. doi: 10.3390/biom10040610.

Assessing the relationship between non-motor symptoms and health-related quality of life in Parkinson's disease: a retrospective observational cohort study

Ueno T, Kon T, Haga R, Nishijima H, Arai A, Tomiyama M.

Neurol Sci. 2020 Oct;41(10):2867-2873. doi: 10.1007/s10072-020-04406-5. Epub 2020 Apr 23.

Effects of a High-Intensity Progressive-Cycle Program on Quality of Life and Motor Symptomatology in a Parkinson's Disease Population: A Pilot Randomized Controlled Trial

Cancela JM, Mollinedo I, Montalvo S, Vila Suárez ME.

Rejuvenation Res. 2020 Dec;23(6):508-515. doi: 10.1089/rej.2019.2267. Epub 2020 Jun 2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias